Recombinant HIV-1 plasmid (derived from pNL4-3) with the indicated mutations in the protease gene, which have been reported in the context of clinical drug resistance to HIV protease inhibitors.
Recombinant HIV-1 virus with the indicated mutations in the protease gene. Mutations have been reported from drug resistant viral variants emerging in vivo, e.g. after treatment with the HIV protease inhibitor saquinavir
Gp41 recombinant, carrying the "MIF" motif, typical for subtype AE, in the fusion domain of the subtype B prototype NL4-3 - for studying the fusion function.
full length proviral HIV-1 genome with a TAG stop codon inserted after position 8368 in gp41 (NL4-3), truncating the intracellular domain of gp41; (a stop codon at analogous position have been reported in early reports of SIV propagation in vitro.)
proviral HIV-1 clone with an inserted TAATGA double stop codon in the endodomain of gp41 after position 8368 (NL4-3); (a stop codon at analogous position have been reported in early reports of SIV propagation in vitro.)
Deletion mutant of HIV-1 with a deleted env gene; RRE reintroduced for the expression of HIV-1 Gag. The genes vpr, env, tat, rev, vpu, nef are not expressed.
